Indivior Provides Update on Aelis Farma's Clinical Trial Results
Indivior PLC (Nasdaq/LSE: INDV) has recently released information about the outcomes of Aelis Farma's Phase 2B clinical trial involving AEF0117. This trial aimed to evaluate the drug's effectiveness in treating Cannabis Use Disorder (CUD). Specifically, the study sought to determine if AEF0117 could significantly decrease cannabis consumption among individuals seeking treatment for moderate to severe dependency.
Study Goals and Key Findings
The primary focus of the Phase 2B study was to assess two critical aspects: first, the effectiveness of AEF0117 at various dosages (0.1, 0.3, and 1 mg taken once daily over a 12-week period) in reducing the frequency of cannabis use among participants; and second, to establish clear endpoints for future research.
Notably, 84% of the participants qualified as having severe CUD. Despite high hopes for the trial, the results showed that neither the main goal—reducing cannabis use to one day a week or less—nor the secondary objective of achieving complete abstinence was met. This outcome presents a significant challenge in tackling severe cases of CUD, underscoring the need for further exploration into the complexities of treating this population.
Indivior's Future Considerations
In response to these findings, Indivior is thoughtfully evaluating its options regarding the licensing agreement for AEF0117 in its ongoing collaboration with Aelis Farma. Given the trial results, the company has decided not to pursue its option for AEF0117 until future studies yield more promising data. This choice reflects Indivior's commitment to ensuring the best possible outcomes before moving forward with any licensing agreements.
Dedication to Patient Care and Ongoing Research
The Phase 2B clinical trial was a vital component of Indivior’s strategic partnership with Aelis Farma, reinforcing the company’s commitment to developing effective treatments for substance use disorders (SUD). Indivior is focused on transforming CUD into a recognized chronic condition that can be managed effectively through evidence-based methods. The company is dedicated to further understanding the mechanisms of CUD, which will inform its future development efforts.
Indivior's Vision
At its core, Indivior strives to ensure that patients around the world have access to high-quality treatments for substance use disorders. The company’s pipeline goes beyond medications for Opioid Use Disorder (OUD), as it explores potential therapies for a variety of chronic conditions linked to substance abuse. As it continues to grow, Indivior aims to innovate through strategic partnerships and robust research initiatives.
A Call for Continued Research
The results of the Phase 2B study highlight an urgent need for ongoing research into effective therapeutic options for CUD. Indivior stresses the importance of understanding the nuances in how patients respond to treatments. By gathering insights from such studies, the company hopes to develop well-informed solutions tailored to the diverse needs of individuals struggling with cannabis dependency.
Frequently Asked Questions
What were the main objectives of the AEF0117 Phase 2B study?
The primary objective was to assess if AEF0117 could reduce cannabis use to one day per week or less among treatment-seeking patients with CUD.
How did the study's results impact Indivior's plans?
Indivior decided not to exercise its option for AEF0117 following the study results, pending further favorable data from future trials.
What is Indivior's focus moving forward?
Indivior aims to deepen its research into CUD while expanding its treatment options for substance use disorders globally.
How is Indivior addressing substance use disorders?
Indivior is committed to innovating therapies and ensuring access to evidence-based treatments for patients suffering from substance use disorders.
Where can I find more information about Indivior?
For additional details about Indivior, visit their official website to explore their portfolio and ongoing research initiatives.
